Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LASSARAB + aPHAD-SE
- Development stage
- Unknown
- Lead developer
- Thomas Jefferson University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LASSARAB + aPHAD-SE is an investigational, adjuvanted, inactivated recombinant viral vector vaccine designed to prevent Lassa fever and rabies. Developed at Thomas Jefferson University, the vaccine utilizes a genetically modified and attenuated rabies virus vector (BNSP strain, derived from SAD B19) engineered to express both the Lassa virus glycoprotein complex (GPC) and the rabies virus glycoprotein. It is formulated with aPHAD-SE, a synthetic TLR-4-activating adjuvant consisting of a monophosphoryl lipid A (MPLA) analog (3D-(6-acyl)-PHAD) in a stabilized squalene oil-in-water nanoemulsion. The vaccine aims to elicit dual humoral immunity against both pathogens. It is currently being evaluated in Phase 1 clinical trials (NCT06546709) for safety and immunogenicity in healthy adults.
- Other names
- Rabies-Vectored Monovalent Lassa Fever VaccineLASSARAB vaccine with aPHAD-SE adjuvantLASSARAB + aPHAD-SEat
02
Targets
TCR (T cell antigen receptor complex)BCR (Immunoglobulin G B Cell Receptor)TLR4 (Toll-like receptor 4)GPC (Lassa virus glycoprotein complex)RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on LASSARAB + aPHAD-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LASSARAB + aPHAD-SE.